Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

J&J takes $13.6 billion charge

Johnson & Johnson said it would take a $13.6 billion charge related to the new U.S. tax law and plans to bring back billions of dollars from overseas immediately.

Read More »

Biotech M&A takes off: Sanofi, Celgene spend $20B

Biotech deal activity exploded with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products to their medicine cabinets.

Read More »

Nuvo Acquires Product Rights from Piedmont

Nuvo Pharmaceuticals acquired the U.S. rights to Resultz head lice treatment from Piedmont Pharmaceuticals.

Read More »

Teva Board Members Take 50 Percent Pay Cut

Teva Pharmaceutical Industries’ board of directors agreed to take a 50 percent pay cut.

Read More »

U.S. pharma executives expect deals to pick up

The Trump administration’s tax overhaul should accelerate major acquisitions by drugmakers in 2018, say senior execs from some of the largest manufacturers.

Read More »

Ablynx Turns Down Novo Nordisk’s Sweetened $3.1 Billion Bid

Novo Nordisk A/S has twice made a bid to acquire Ablynx NV, and twice been rejected.

Read More »

Celgene to Acquire Impact Biomedicines

Celgene Corporation will acquire Impact Biomedicines – which is developing fedratinib for myelofibrosis and polycythemia vera – for $1.1 billion upfront.

Read More »

Denali Scores $1B+ Alzheimer’s Deal With Takeda

Takeda CEO Christophe Weber is sticking to his game plan of actively hunting deals that will expand its global presence and create a stronger international profile.

Read More »

Takeda Takes Out TiGenix in $630 Million Deal

Shares of Belgium-based TiGenix NV shot up after Japan’s Takeda Pharmaceutical opted to acquire the company for $630 million.

Read More »

Pernix Cuts 22 Percent of Workforce in Reorganization

Pernix Therapeutics is undergoing a reorganization that includes the termination of a number of sales representatives.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom